Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
759.63-
QQQ
704.231.49%
BTC/USD
77718.671.1964%
DIA
524.650.22%
GLD
393.781.25%
TLT
80.88-

Arcutis Biotherapeutics Inc

ARQTNASDAQ
Trade with Public
Trade with Public
$23.89
0.512.16%
At close: Sep 10, 5:00 PM EST
$23.86
0.482.05%
Pre-Market: 7:23 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Arcutis Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcutis Biotherapeutics (ARQT).

Price Target Range — 13 Quarters

Analyst Consensus — 9 Analysts

7Buy
2Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$29Upside to Avg. PT+22.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026Morgan StanleyVikram PurohitPT RaiseOverweight$34→$38
Aug 6, 2026GuggenheimSeamus FernandezPT RaiseBuy$35→$38
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
Benzinga Newsdesk

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lowers the price target from $37 to $35.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $35

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $34 to $35.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved